Who is sponsoring NCT01902758?

NCT01902758 is sponsored by University of Montana.

What condition does NCT01902758 study?

NCT01902758 studies Acute Mountain Sickness.

What drugs are being tested in NCT01902758?

Interventions: ambrisentan and theophylline, placebo.

What is the status of NCT01902758?

NCT01902758 is currently COMPLETED.

Last reviewed 2016-01-28 · How we verify

Enhancing Physical Performance and Mitigating Acute Mountain Sickness Via Pharmaceutical Intervention While at Altitude

NCT01902758 Phase 2/Phase 3 COMPLETED Results posted

This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.

Details

Lead sponsor	University of Montana
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	28
Start date	2013-08
Completion	2013-08

Conditions

Acute Mountain Sickness

Interventions

ambrisentan and theophylline
placebo

Primary outcomes

Time (Minutes) to Complete 2 Miles on a Treadmill — after arriving at high altitude (within 1 hour)

Countries

United States